Active Ingredient History
Glatiramer acetate, sold under the brand name Copaxone among others, is an immunomodulator medication used to treat multiple sclerosis. Glatiramer acetate is approved in the United States to reduce the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that it may reduce progression of disability. While a conclusive diagnosis of multiple sclerosis requires a history of two or more episodes of symptoms and signs, glatiramer acetate is approved to treat a first episode anticipating a diagnosis. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Amyotrophic Lateral Sclerosis (Phase 2)
Carcinoma, Basal Cell (Phase 1)
Carcinoma, Squamous Cell (Phase 1)
Crohn Disease (Phase 2)
Cytokine Release Syndrome (Phase 2)
Diabetic Retinopathy (Phase 4)
Glaucoma (Phase 3)
Heart Failure (Phase 2)
Inflammation (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Macular Degeneration (Phase 2/Phase 3)
Multiple Sclerosis, Chronic Progressive (Phase 2/Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 4)
Optic Neuritis (Phase 3)
Rett Syndrome (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
